Novartis' in-development multiple myeloma candidate LBH589 hit its primary endpoint of staving off cancer progression in a late-stage study, the company said, stoking hopes the Swiss drugmaker can take first place among a new class of treatments.
Princeton University will not begin to offer Novartis' meningitis B vaccine to Bexsero to students until next week, but health officials are already considering expanding the campaign to another university. An outbreak at the University of California, Santa Barbara, is the cause of the latest concerns.
Unilife is at it again. This time it's Novartis signing a deal with the injectable technology provider, adding to Unilife's impressive list of recent agreements with top pharmaceutical companies Sanofi, MedImmune and Hikma.
Just weeks after selling its blood-transfusion business and announcing a new strategy focusing on pharmaceutical development, Novartis is reportedly opening the books on its animal-health business to potential buyers. Bayer may be the top suiter.
Novartis scientists, in collaboration with an international team of researchers from the University of California, San Diego, and Columbia University, have identified a novel drug target for treating malaria, a scourge of many tropical Third World countries.
Two buyout firms are duking it out for LTS Lohmann, a drug-patch maker partly owned by Novartis, Reuters reports. Now that the dust has settled on first-round bids, which were due last month, Wendel and Nordic Capital are still in the running for a deal worth about $1.6 billion.
LTS Lohmann, which Novartis owns a big piece of, is reportedly attracting bids of about $1.6 billion from private equity investors who want its expertise in the growing niche of manufacturing transdermal patches.
Long-running speculation about the future of Novartis' struggling vaccine business now appears to be nearing an end. One way or another, Novartis CEO Joe Jimenez expects the future of the unit to be settled in the coming months.
After Novartis's investor day, the spotlight quickly moved to the company's $5 billion buyback plan. CEO Joe Jimenez and his team also unveiled some details--a few, at least--about the company's strategic review.
Speaking at an investor day late last week, Novartis chief financial officer Harry Kirsch outlined how the company plans to generate "substantial savings" by working with external data management vendors.